A Short Review on Medication-Overuse Headache

A. Krymchantowski
{"title":"A Short Review on Medication-Overuse Headache","authors":"A. Krymchantowski","doi":"10.4172/2376-0281.1000284","DOIUrl":null,"url":null,"abstract":"Background and objective: Medication-overuse headache (MOH) is a disabling and highly prevalent disease in neurologic clinics. Little evidence is available regarding treatment, but the suspension of overused medications, treatments using multidisciplinary approaches as well as absence of psychiatric comorbidities and overuse of drugs other than opioids are favorable outcome factors. Methods: We described key patient’s characteristics and treatment strategies carried out on consecutive patients with MOH from a specific tertiary center. The patients were submitted to a comprehensive approach with long-lasting initial consultations. The withdrawal of overused medications was conducted in all patients to whom different drugs for prevention were prescribed as well as the combination of a triptan plus an anti-inflammatory drug (NSAID) in a maximum intake of 2 days/week. Prednisone, as a bridge to detoxification, was given to 67.8% of the patients during the first 5-7 days. Results: After two months, 20.1% of the patients were lost to follow up and the mean headache frequency, among those who adhered, decreased to 10.7 headache days/month. After four and eight months, most of the patients were still under treatment with a mean headache frequency of 7.6 and 8.3 headache days/month. An intention to treat (ITT) analysis was also accomplished. After eight months, relapses or the use of symptomatic medications in 10 or higher days per month was observed in 23.8% of the patients (ITT 36.2%). Conclusion: The majority of patients with MOH undergoing comprehensive treatments show marked reduction in headache frequency, return to episodic presentation pattern and acceptable compliance with treatment directives despite previous therapeutic failures. Patient education, thorough evaluation and strict follow up even with patients previously seen as refractory, can lead to optimal clinical outcomes. Controlled studies on different treatment strategies are warranted.","PeriodicalId":91292,"journal":{"name":"International journal of neurorehabilitation","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2376-0281.1000284","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of neurorehabilitation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2376-0281.1000284","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background and objective: Medication-overuse headache (MOH) is a disabling and highly prevalent disease in neurologic clinics. Little evidence is available regarding treatment, but the suspension of overused medications, treatments using multidisciplinary approaches as well as absence of psychiatric comorbidities and overuse of drugs other than opioids are favorable outcome factors. Methods: We described key patient’s characteristics and treatment strategies carried out on consecutive patients with MOH from a specific tertiary center. The patients were submitted to a comprehensive approach with long-lasting initial consultations. The withdrawal of overused medications was conducted in all patients to whom different drugs for prevention were prescribed as well as the combination of a triptan plus an anti-inflammatory drug (NSAID) in a maximum intake of 2 days/week. Prednisone, as a bridge to detoxification, was given to 67.8% of the patients during the first 5-7 days. Results: After two months, 20.1% of the patients were lost to follow up and the mean headache frequency, among those who adhered, decreased to 10.7 headache days/month. After four and eight months, most of the patients were still under treatment with a mean headache frequency of 7.6 and 8.3 headache days/month. An intention to treat (ITT) analysis was also accomplished. After eight months, relapses or the use of symptomatic medications in 10 or higher days per month was observed in 23.8% of the patients (ITT 36.2%). Conclusion: The majority of patients with MOH undergoing comprehensive treatments show marked reduction in headache frequency, return to episodic presentation pattern and acceptable compliance with treatment directives despite previous therapeutic failures. Patient education, thorough evaluation and strict follow up even with patients previously seen as refractory, can lead to optimal clinical outcomes. Controlled studies on different treatment strategies are warranted.
药物滥用性头痛研究综述
背景与目的:药物过度使用头痛(MOH)是神经科临床中一种致残且高发的疾病。关于治疗的证据很少,但暂停过度使用药物,使用多学科方法进行治疗,以及没有精神合并症和过度使用阿片类药物以外的药物是有利的结果因素。方法:我们描述了关键患者的特征和对来自特定三级中心的连续MOH患者进行的治疗策略。患者被提交到一个全面的方法与长期的初步咨询。所有服用不同预防药物以及曲坦类药物加抗炎药(NSAID)的患者均进行了过度用药的停药,最多服用2天/周。泼尼松作为排毒的桥梁,67.8%的患者在前5-7天服用了泼尼松。结果:2个月后,20.1%的患者失去随访,坚持治疗的患者平均头痛频率降至10.7天/月。4个月和8个月后,大多数患者仍在接受治疗,平均头痛频率分别为7.6和8.3天/月。还完成了意向治疗(ITT)分析。8个月后,23.8%的患者复发或每月使用症状性药物10天或以上(ITT 36.2%)。结论:大多数接受综合治疗的MOH患者头痛频率显著降低,恢复发作性症状,尽管先前治疗失败,但对治疗指示的依从性可接受。患者教育,彻底的评估和严格的随访,即使是以前被认为是难治性的患者,也可以导致最佳的临床结果。需要对不同治疗策略进行对照研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信